- Benzinga
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
On Wednesday, Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna (inebilizumab-cdon) for Immunoglobulin G4-related disease, a systemic autoimmune fibroinflammatory multiorgan disease, usually involving the pancreas. Amgen added Uplizna via a $27.8 billion acquisition of Horizon Therapeutics and recorded sales of $80 million in the first quarter of 2024. The trial met its primary endpoint, showing a statistically significant 87%
- Yahoo Sports
Celtics trust issues, LeBron's free agency & NBA Finals predictions | Good Word with Goodwill
Vincent Goodwill and Tom Haberstroh preview game 1 of the 2024 NBA Finals, explain why they don’t trust the Celtics & wonder if LeBron might be switching teams this offseason.
- AFP
UN nuclear watchdog board passes resolution criticising Iran
The UN nuclear watchdog's board of governors has passed a resolution criticising Iran's lack of cooperation with the agency, diplomats told AFP on Wednesday, a decision Tehran slammed as "hasty and unwise".Iran's mission to the United Nations said the censure motion was "hasty and unwise" and would "undoubtedly have a destructive effect on the process of diplomatic interaction and constructive cooperation", ISNA news agency quoted it as telling the Al-Monitor news website.
